関連する実験動画
Updated: May 2, 2026

11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.0K
牛皮病の治療における新しいリン酸エステラゼ4阻害剤の体系的レビュー
Amirreza Fakhri Baghdad Abad1, Nazila Heidari1, Zahra Lotfi2
1School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
まとめ
新しいフォスフォディエステラゼ4 (PDE-4) 阻害剤は,牛皮病の治療に有望であることが示されています. 経口および局所投与のPDE-4阻害剤は,この慢性皮膚疾患の患者に有効な緩和と良好な安全性プロファイルを提供します.
科学分野:
- 皮膚科
- 免疫学
- 薬理学について
背景:
- 牛皮病は慢性で免疫媒介の皮膚疾患で 身体的,心理的,全身的な影響を及ぼします
- フォスフォディエステラゼ4 (PDE-4) 阻害剤は,循環性アデノシンモノフォスファート (cAMP) レベルを調節し,牛皮病の炎症に重要な役割を果たします.
- このレビューでは,新興のPDE-4阻害剤の臨床効果と安全性を評価しています.
研究 の 目的:
- 新種のPDE-4阻害剤の臨床効果を体系的に検討する.
- これらの新興PDE-4阻害剤の安全性を評価する.
- 牛皮病の管理のためのPDE-4阻害剤に関する現在の証拠を特定する.
主な方法:
- PubMed/Medline,Embase,Web of Scienceのデータベースで体系的な文献検索が行われました.
- 2025年1月18日までに発表された,症に対するPDE-4阻害剤を含む研究が含まれています.
- 方法論的品質とバイアスのリスクはNIHとMurad et alを用いて評価された. ツール
主要な成果:
- 642人の患者を対象とした12件の研究は,含有基準を満たした.
- 経口用ロフルミラスト,オリスミラスト,ME3183は,常見の副作用として胃腸の問題とともに,症の重度 (PASI) と生活の質 (DLQI) の有意な改善を示した.
- 局所用クリサボロールとPF- 07038124は,軽度から中度までのの症例において,最小限の副作用で,迅速かつ局所的な反応を示した.
結論:
- 経口および局所投与のPDE-4阻害剤は,牛皮病の治療において有望な効果と許容可能な安全性を示しています.
- 長期的な効果を確認し,臨床適用を最適化するために,延長されたフォローアップによるさらなる大規模な研究が必要である.
- PDE-4 阻害剤は,牛皮病の治療における潜在的な進歩を表しています.
関連する概念動画
Protein Kinases and Phosphatases
12.1K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
12.1K
Phosphoinositides and PIPs
7.7K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
7.7K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
823
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
823
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K

